[Melanoma in organ transplant patients].

Laure Lévêque(CHU Dijon Bourgogne), D Lambert, J. Chevrant‐Breton, Pascal Daguin, Y. Tanter, C. Françès(Navarre Institute of Health Research), S. Dalac(CHU Dijon Bourgogne), S Euvrard, B. Catteau(Centre Hospitalier Universitaire de Lille), M Schollhamer, F. Aubin(Centre Hospitalier Universitaire de Besançon), M J Bismuth, S Louvet, Brigitte Dréno(Nantes Université), Marc Hazan, A. Dompmartin(Centre Hospitalier Universitaire de Caen Normandie)

PubMed

February 1, 2000

Cited by 44

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

|New England Journal of Medicine|2011|7.7k

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

|New England Journal of Medicine|2014|2k

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

|Journal of Clinical Oncology|2000|1.3k

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

|The Lancet|2023|1.1k

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

|The Lancet Oncology|2016|1k